Previous 10 | Next 10 |
home / stock / gnmsf / gnmsf news
Fresenius Medical Care ( FMS +1.5% )( OTCPK:FMCQF )( OTCPK:FSMEM ) assumed with Hold rating and €82 price target at Jefferies. More news on: Fresenius Medical Care AG & Co. KGAA, Fresenius Medical Care AG & Co KGaA, Fresenius Medical Care Holdings, Healthcare stocks news, ...
As expected, the European Commission approves Johnson & Johnson (NYSE: JNJ ) unit Janssen Biotech's DARZALEX (daratumumab), combined with Takeda Pharmaceutical's ( OTCPK:TKPYY ) VELCADE (bortezomib), melphalan and prednisone, for the treatment of adult patients with multiple myeloma in...
Genmab A/S (GNMSF) Q2 2018 Earnings Conference Call August 08, 2018, 12:00 ET Executives Jan van de Winkel - Co-Founder, CEO & President David Eatwell - EVP & CFO Analysts James Quigley - JPMorgan Chase & Co. Wimal Kapadia - Sanford C. Bernstein & Co. Pet...
The following slide deck was published by Genmab A/S in conjunction with their 2018 Q2 earnings Read more ...
Genmab ( OTCPK:GNMSF ): Q2 EPS of DKK4.21 More news on: Genmab A/S, Genmab A/S ADR, Earnings news and commentary, Tech stocks news, Read more ...
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Janssen headlines myeloma therapy in Europe Company: Johnson & Johnson ( JNJ ) and G...
Genmab A/S ( OTCPK:GNMSF -20% ) slumps on the news that collaboration partner Johnson & Johnson ( JNJ -1.2% ) has scrapped an early-stage study assessing the combination of DARZALEX (daratumumab) + Roche's TECENTRIQ (atezolizumab) in second-line lung cancer due to lack of efficacy ...
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. AstraZeneca marks a new historic achievement in competitive lung cancer space Company: As...
Verastem ( VSTM +5.1% ) is up on average volume in apparent response to Genmab's ( OTCPK:GNMSF )( OTCPK:GMXAY ) failed late-stage study of Arzerra (ofatumumab) in indolent B-cell non-Hodgkin lymphoma. Ofatumumab, a CD-20-directed monoclonal antibody, is currently approved in the U.S. t...
Genmab A/S ( OTCPK:GNMSF )( OTCPK:GMXAY ) announces that a Phase 3 clinical trial evaluating Arzerra (ofatumumab) plus bendamustine in patients with indolent B-cell non-Hodgkin lymphoma (iNHL) who have not responded to Roche's Rituxan (rituximab) failed to demonstrate a statistically ...
News, Short Squeeze, Breakout and More Instantly...
Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE ® NHL-1 study FL is the second most common type of NHL and accounts for approximately 20-30 percent of all global cases If approved, epcoritamab (TEPKINLY ® ...
Company Announcement Genmab has completed acquisition of ProfoundBio for USD 1.8 billion in cash Acquisition gives Genmab worldwide rights to three candidates in clinical development, including rinatabart sesutecan (Rina-S), plus ProfoundBio’s novel antibody-drug conjugat...
May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024 Highlights The U.S. Food and Drug Administration (U.S. FDA) granted Priority Review for the supplemental Biologics License Application (sBLA) for EPKINLY ® (epcorita...